Skip to main content
Integrative Cancer Therapies logoLink to Integrative Cancer Therapies
. 2015 Nov 25;15(1):113–123. doi: 10.1177/1534735415617282

A Chinese Decoction, Kuan-Sin-Yin, Improves Autonomic Function and Cancer-Related Symptoms of Metastatic Colon Cancer

Tsai-Ju Chien 1,2, Chia-Yu Liu 1,3, Pin-Hao Ko 4, Chung-Hua Hsu 1,3,
PMCID: PMC5736084  PMID: 26612784

Abstract

Background

Kuan-Sin-Yin (KSY) is a traditional Chinese medicine (TCM) decoction, which has been shown to have cytostatic effects on cancer cells and involved in the TCM theory of promoting yin-yang balance.Sonce many cancer patients suffer from autonomic dysfunction (AD), which correspond to yin-yang imbalance in TCM. The aim of this study is to evaluate the possible effect of KSY in metastatic colon cancer (mCRC) patients with AD.

Methods

We conducted a single-group experiment. Total 52 qualified patients were enrolled. Participants took the KSY daily for 2 weeks. The primary outcome was KSY efficacy as reflected in the heart rate variability (HRV) and electrical conductivity (µA) over 12 meridian points. Autonomic function was examined before and after the KSY intervention. The vagal and sympathetic tone were recorded by HRV; 12 meridian energies were measured using a meridian energy analysis device. Secondary outcomes were cancer-related symptoms and patient quality of life (QoL).

Results

The results showed that the KSY intervention improved AD via increasing the vagal tone (HF: P = .041), but not the sympathetic tone (LF: P = .154); total autonomic activity was significantly enhanced (HRV activity: P = .013). Intriguingly, energy increased more over the yin meridian (P = .010) than over the yang meridian (P = .015). Cancer-related symptoms and QoL were significantly improved (P < .05).

Conclusion

The safety and effectiveness of KSY in improving AD in mCRC patients are through regulating the vagal-sympathetic dynamic balance, which correspond to the TCM yin-yang concept of energy.

Keywords: autonomic dysfunction, autonomic nervous system diseases, heart rate variability, Kuan-Sin-Yin, yin-yang, traditional Chinese medicine

Introduction

In recent decades, cancer has become one of the most important health issues because of its high prevalence and the associated death rate. Beyond the standard Western options of chemotherapy and target therapy, more and more natural compounds and traditional Chinese medicine (TCM) treatments have been accepted as a part of cancer treatment. TCM may enhance the physical energy (qi) and has a positive effect on organ function. Many cancer patients suffer from autonomic dysfunction (AD), a disturbance in the organ function regulated by the vagal and sympathetic nerve systems, a condition that corresponds to the TCM concept of an imbalance in the yin and yang energy forces within the human body. Studies have found AD to be highly prevalent in patients with advanced cancer, and it is associated with the worsening of fatigue and related symptoms as well as poor survival.1 The autonomic nervous system (ANS) controls the blood vessels, airways, intestines, and cardiovascular system and is mostly under involuntary control. It regulates and coordinates bodily functions through glandular activity and the contraction and relaxation of smooth and cardiac muscles.2 Many studies have shown that AD in advanced cancer, whether in the cardiovascular, digestive, or endocrine system, leads to lower quality of life (QoL).3,4 The TCM decoction Kuan-Sin-Yin (KSY) has been proved to be safe and effective in upregulating the qi energy and improving QoL in cancer patients.5,6 The design of KSY is based on the classic decoction si jun zi tang, which has been used in TCM for thousands years with the effect of qi promotion and immunity enhancement.7,8 In regard to the composition of the KSY, it is a TCM decoction that is composed of 7 herbs in a specified ratio (Codonopsis pilosula 6 g; Atractylodes macrocephala 6 g; Glycyrrhiza uralensis 3 g; Poria cocos 6 g; Astragalus membranaceus 6 g; Ligustrum lucidum 3 g; and Agastache rugosa 6 g; net weight of 36 g of herbal medicine was extracted with 100 mL water in each pack). All herbs were soaked in water at a ratio of 1:3 (g:mL) and subsequently boiled at 1.5 atm,120°C, for 4 hours using an automatic Chinese herb boiling machine.5,9 We are intrigued by the effect of KSY on AD in cancer patients. Because the serum levels and tumor markers of biochemistry cannot represent the activity or balance of the autonomic system, we chose alternative tools to measure heart rate variability (HRV) and skin conductivity over specific acupoints to evalulate the effect of KSY on AD. The relevance of skin conductivity in AD was based on Ryodoraku theory.10,11 There are also some studies measuring the correlation of electroconductivity and the disease.12,13 According to a previous study, the skin conductivity measured by the meridian energy analysis device (MEAD) provides both reliable and significant results for analysis of the meridian energy and the index of the vagal-sympathetic balance; the reproducibility of the device is 93.2%.10 Therefore, we checked the changes in the electrical conductivity to compare the severity of AD in patients.

Recent research has shown that HRV has good specificity and positive predictive value for the diagnosis of AD and can be used as a reliable diagnostic method in cancer patients.14 Chien et al15 also demonstrated that electrical skin conductivity may reflect the activity of the ANS, in concordance with the TCM meridian theory.

Patients’ self-reported QoL and cancer-related symptoms were also investigated in the study. The study was focused on patients with metastatic colon cancer (mCRC), a homogeneous group of individuals who received similar chemotherapy treatment. The study involved an intervention and measurements that were noninvasive, safe, and inexpensive. In this study, the TCM concept of keeping the physical function in hormony and elevating the meridian energy (qi) corresponded well with the Western notion of regulating the vagus/sympathetic nerve tone to treat AD.

Objectives and Hypotheses

In this study, HRV physiological parameters and meridian energy (qi) levels reflected in skin conductivity were measured across 2 weeks of KSY use in mCRC patients to objectively evaluate the effects of KSY on AD. We hypothesized that, after controlling for cancer type, disease status, and related chemotherapy regimens, significant differences in HRV parameters and skin conductivity before and after the KSY intervention would identify the improvements in AD and qi meridian energy levels.

Materials and Methods

Research Design and Participants

An experimental clinical research design was applied in this study. With the cooperation of the Chinese Medical and Oncology Department, the attending physicians, including TCM doctors and oncologists, assigned the participants to supervise interventions. The inclusion criteria were as follows: (1) cancer pathology confirmed with mCRC; (2) patients with Eastern Cooperative Oncology Group (ECOG) performance scores ≤2 and 20 to 75 years old; (3) patients who sufferred from more than 4 of 9 symptoms graded more than 1, identified as having at least moderate AD (we meaured 9 cancer-related and AD symptoms using the Common Terminology Criteria for Adverse Events [CTCAE] criteria, as shown in Table 1); (4) participants who completed chemotherapy with an oxaliplatin- or irinotecan-based regimen within the past 6 months and with at least moderate AD and cancer-related symptoms; (5) all participants who were able to understand the purpose and process of this study and signed the informed consent form.

Table 1.

Comparison of Cancer-Related Symptoms Before and After Kuan-Sin-Yin Intervention (n = 52).a

CTCAE Before, n (%) After, n (%) P Value
Grade >1
Fatigue 19 (36.5) 8 (15.4) .001**
Anemia 2 (3.8) 5 (9.6) .461
Pain 11 (21.2) 7 (13.5) .032*
Diarrhea 3 (5.8) 4 (7.7) .157
Constipation 6 (11.5) 4 (7.7) .077
Nausea 21 (40.4) 5 (9.6) .0001***
Vomiting 6 (11.5) 3 (5.8) .026*
Anorexia 24 (46.1) 9 (17.3) .0001***
Insomnia 21 (40.4) 9 (17.3) .022*
Performance ECOG score >1 22 (42.3) 5 (9.6) .0001***

Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events (grading: 0-4); ECOG, Eastern Cooperative Oncology Group.

a

Grade 0, no symptoms; grade 1, mild symptoms; grade 2, symptomatic and medical intervention or minor cauterization indicated; grade 3, severe symptoms, daily-life function disability; grade 4, life-threatening adverse event. *P < .05; **P ≤ .001; *** P ≤ .0001 with statistical significance.

Patients meeting the following criteria were excluded: (1) terminal disease or life expectancy <3 months; (2) presence of psychiatric problems; (3) completion of the chemotherapy treatment course; (4) development of a major event (operation, acute myocardial infarction, severe infection such as pneumonia, or under ventilator use) causing withdrawal from the study; or (5) any other condition the physician-in-charge deemed would make the patient unsuitable for the study.

All participants were given the TCM decoction KSY (100 cc) every day after breakfast to relieve their AD and cancer-related symptoms for 2 weeks after the chemotherapy. The study protocol and design were reviewed and approved by the Taipei City Hospital Institutional Review Board (reference number: TCHIRB-1020127-E) and then implemented from July 2013 to December 2014 in Lin-Sen Branch, Taipei City Hospital. Verbal and written informed consent were obtained from all participants after they were informed of the study design, intervention, data collection, and the rights of participants. Figure 1 shows the flowchart of the research design and participant enrollment in this study.

Figure 1.

Figure 1.

Study flowchart.

Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; WHO, World Health Organization; SF12, 12-Item Short Form Health Survey.

Intervention

The TCM decoction KSY we used in this study was designed to enhance the qi meridian energy, which may regulate the autonomic function.

Quality Control and Safety of KSY

The KSY contained 7 Chinese herbs (Codonopsis pilosula, Atractylodes macrocephala, Poria cocos, Astragalus membranaceus, Agastache rugosa, Ligustrum lucidum, and Glycyrrhiza uralensis). Each of the components has been shown to have pharmacological activity in modulating the immune system and to have anti-inflammatory or antioxidant properties or both.16-22 The purity of the KSY was evaluated by screening ingredients for contamination by heavy metals and pesticides and by a microbial limit test. Standard contents and quality control were analyzed by Internal Transcribed Space (ITS) technology and high-performance liquid chromatography (HPLC) at the Industrial Technology Research Institute, Hsinchu, Taiwan.We used ITS to analyze each of the 7 component ingredients in KSY to establish their DNA sequence, then analyzed the final KSY decoction using HPLC-PCA.23 ITS is a well-developed DNA technology used to authenticate Chinese herbal ingredients; it analyzes a piece of nonfunctional RNA situated between structural ribosomal RNAs (rRNA) on a common precursor transcript.24 The DNA sequence of each component herb has been well defined previously. The HPLC chromatograph of KSY and the DNA sequences of the component herbs are provided in Supplementary Material 1 (available at http://ict.sagepub.com/supplemental). Another study indicated the safety and efficacy of KSY in improving liver function.25 A pilot study showed that KSY improved the QoL in cancer patients based on the TCM concept of supplying qi energy.5

Because KSY has been shown to safely suppress tumor growth in vivo and in vitro,9 we used KSY in mCRC patients to observe the effect on AD.

Measurements and Study Settings

The primary outcomes were the efficacy of KSY as reflected in HRV parameters and electrical conductivity over 12 meridians. The secondary outcomes were improvements in cancer-related symptoms and QoL measurements after the KSY intervention. Because this is a pragmatic study, in the real world, patients may have some belief (or disbelief) of the benefit of TCM in relieving their cancer-related symptoms. However, except for the self-reported QoL assessment, the HRV and meridian energy measurement along with the cancer-related symptom grading (according to CTCAE) were recorded by an assistant who was not otherwise involved in the study. to minimize the bias.

Measurements of HRV and electrical conductivity (meridian energy, qi) were done by a well-trained technician before and after the participants received KSY treatment for 2 weeks. Both procedures were done with participants lying down, after a 15-minute rest, and in a quiet room with a constant temperature of 25°C and humidity of 55%. Self-report of cancer-related symptoms and the QoL questionaire were also administered before and after the KSY intervention.

Analysis of Heart Rate Variability

For each participant, both frequency-domain and time-domain HRV were measured according to the Task Force of the ESC and NASPE using the ANSWatch analysis system26 (Figure 2). The following HRV parameters were calculated as hourly values: standard deviation of adjacent peak-to-peak intervals (SDNN), which reflect the total ANS activity index (ms), and square root of the mean of the sum of the squares of differences between adjacent peak-to-peak intervals (RMMSD). The power spectra of peak-to-peak intervals were obtained by means of fast Fourier transformation (Taiwan Scientific Corporation, Shin-Dian City, Taipei 231, Taiwan). The zero-frequency component was excluded before the calculation of powers. The area under the curve of the spectral peaks within the ranges of 0.01 to 0.4 Hz, 0.01 to 0.04 Hz, 0.04 to 0.15 Hz, and 0.15 to 0.4 Hz were defined as the total power (TP), very-low-frequency power (VLF), low-frequency power (LF), and high-frequency power (HF), respectively. The HF was used as the index of vagal tone and the LF as the index of sympathetic and vagal modulation; LF/HF was the index of sympathetic-vagal balance.27

Figure 2.

Figure 2.

ANSWatch wrist monitor.

The accuracy of the ANS monitor was represented by the correlation between the HRV parameters and electrocardiogram results.28 The findings of Fadul et al29 suggest that HRV may provide a useful measure of AD in advanced cancer patients.

Meridian Energy

We checked the electrical conductivity in the 12 modified Yuan (source) acupoints over 12 meridians with a MEAD (MedPex, Taipei, Taiwan; Figure 3). The 12 modified Yuan source acupoints are near the wrist or ankle joins of the 4 extremities and may represent the vital energy of the 12 meridians (6 yin and 6 yang meridians) and the correponding organs (Figures 4A-4D). TCM uses the 12 modified yuan (source) points to treat diseases of the internal organs. MEAD has been shown in other clinical studies to provide both reliable and significant results for analysis of the meridian energy and the index of the vagal-sympathetic balance.6,15,30,31 The measurements were started with very low current and gradually increased to a maximum value of 200 µA. Recordings of the electrical conductivity of the meridians were entered directly into a computerized system. The conductivity values were calculated with voltage supplied by the device and currents measured in meridians and were expressed on a scale from 0 (zero conductivity) to 100 (maximum conductivity). The conductivity value of the 12 modified yuan (source) acupoints and the mean value of the yin/yang meridian of each patient were calculated once at each time point (before and after intervention).

Figure 3.

Figure 3.

Meridian energy analysis device (MEAD).

Figure 4.

Figure 4.

A. Acupoints in the yin meridian of the hand. B. Acupoints in the yin meridian of the foot. C. Acupoints in the yang meridian of the hand. D. Acupoints in the yang meridian of the foot.

Cancer-Related Symptoms and QoL

Cancer-related symptoms were graded using the Common Terminology Criteria for Adverse Events (CTCAE) Scale, a tool commonly used in clinical evalulation of the grade of cancer-related symptoms.32 We also had participtants fill out 2 QoL questionaires: the Brief World Health Organization Quality of Life Questionnaire (WHO-BREF) and the 12-Item Short Form Health Survey (SF-12).33,34

Statistical Analysis

The data were analyzed using IBM SPSS 19.0 for Windows (IBM Corp, Endicott, NY). Demographic details and clinical variables were summarized using descriptive statistics. The results of HRV with distribution plot were calculated by MedCalc software version 15.2.

A paired-t and nonparametric 2-sample t test with Wilcoxon signed-rank test were used to compare the differences before and after the KSY intervention in HRV and meridian energy, cancer-related symptoms, and QoL. The statistical hypothesis tests were set with a significance level of .05.

Results

Participant Characteristics

After assessment for eligibility, 52 mCRC patients were included in the study. Table 2 shows the demographic characteristics of the participants. Their mean age was 51.42 years. All were well educated and communicated well, with ECOG scores ≤2.

Table 2.

Characteristics of the Participants (n = 52).

Characteristics n (%)
Age group (years)
 0-39 7 (13.5)
 40-49 7 (13.5)
 50-59 34 (65.4)
 60-69 2 (3.8)
 >70 2 (3.8)
Mean (SD) 51.42 (9.5)
Sex
 Male 24 (46.2)
 Female 28 (53.8)
Education
 Senior high school 18 (34.6)
 College 34 (65.4)
ECOG score
 0 5 (9.6)
 1 25 (48.1)
 2 22 (42.3)

Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group.

The Effect of KSY on HRV Parameters

Table 3 and Figure 5 show the analysis of HRV parameters before and after the KSY intervention. The nonsignificant P value of the test pressure (P = .154) indicates the stability of the HRV test before and after the intervention. We noted a significant increase in HF (P = .041), SDNN (indicating HRV activity; P = .013), RMMSD (P = .029), but no significant changes in TP, LF, or sympathetic-vagal balance (LF/HF) indexes. Even though both the vagal tone (HF) and sympathetic tone (LF) increased, the level of increase for the LF (P = .154) was less than for the HF (P = .041), so that the sympathetic-vagal index (LF/HF) did not change significantly. KSY had much greater effect on vagal tone than on sympathetic/vagal tone in this study.

Table 3.

Comparison of HRV and Electrical Conductivity Before and After the Kuan-Sin-Yin Intervention (n = 52).a

Parameter Before, Mean (SEM) After, Mean (SEM) P Value
SDNN (ms) 71.13 (11.41) 95.77 (13.67) .013b
LF (ms2) 766.42 (236.52) 1109.63 (304.18) .154
HF (ms2) 1384.62 (336.48) 2161.88 (459.46) .041b
LF% 40.38 (3.26) 39.28 (3.02) 1.00
HF% 59.62 (3.26) 60.51 (3.02) .952
LF/HF 1.09 (0.27) 1.02 (0.22) .776
Total power (ms2) 8341.18 (2121.37) 12 027.01 (2266.75) .093
VLF (ms2) 6190.11 (1661.06) 8756.02 (2260.04) .081
Variance (ms2) 9797.50 (2859.37) 16 599.81 (3849.95) .013b
RMMSD (ms) 88.71 (12.25) 119.79 (16.06) .029b
Test pressure 58.89 (2.17) 60.95 (1.97) .154
SBP (mm Hg) 115.15 (12.33) 112.94 (13.89) .174
DBP (mm Hg) 76.54 (8.99) 76.46 (11.13) .968
HR (times) 86.12 (13.56 81.29 (12.88) .027b

Abbreviations: HRV, heart rate variability; SEM, standard error of the mean; SDNN, standard deviation of adjacent peak-to-peak (NN) intervals; LF%, low-frequency component normalized; HF%, high-frequency component normalized; LF/HF, sympathetic nerve/parasympathetic nerve balance; VLF, very-low-frequency power; RMMSD, square root of the mean of the sum of the squares of differences between adjacent NN intervals; SBP, systolic blood pressure; DBP, diastolic blood pressure.

a

Total power: variance of NN intervals in FFT analysis (ms2). LF: 0.04 to 0.15 Hz (ms2; measure of sympathetic function). HF: 0.15 to 0.4 Hz (ms2; measure of parasympathetic function). Variance: square of standard deviation of 5-minute NN intervals (ms2).b P < .05 with statistical significance.

Figure 5.

Figure 5.

A. Comparison of the high-frequency component (HF), and low-frequency component (LF) before and after Kuan-Sin-Yin intervention in heart rate variability (HRV) analysis. B. Comparison of standard deviation of adjacent peak-to-peak (NN) intervals (which represent the total HRV activity) and the square root of the mean of the sum of the squares of differences between adjacent NN intervals before and after Kuan-Sin-Yin intervention in HRV analysis. C. Comparison of ratio of LF and HF before and after Kuan-Sin-Yin intervention in HRV analysis. Data are expressed as means and 95% confidence interval for mean.

The Effect of KSY on Electrical Conductivity as Measured With MEAD

Table 4 shows the qi meridian energy level as reflected in electrical conductivity (µA). The normal range of the meridian electrical conductivity is 30 to 64 µA. We found that the average of electrical conductivity of both the yin and yang meridians were lower than normal range, indicating abnormally low qi energy in mCRC patients; however, the mean electrical conductivity of the yin and yang meridians were not significantly different before the KSY intervention (yin meridian: 25.33 µA; yang meridian: 26.10 µA; P = .904). After the KSY intervention, we noted an obviously greater increase in the electrical conductivity in the yin meridians than in the yang meridians. Electrical conductivity increased significantly in all 6 of the yin meridians but in only 2 of the yang meridians.

Table 4.

Comparison of Yin and Yang Meridian Energy Before and After Kuan-Sin-Yin Intervention (Measured With the Meridian Energy Analysis Device); n = 52.

Electrical Skin Conductance (µA)
Before, Mean (SEM) After, Mean (SEM) P Value
Yin Meridian (Acupoint)
 Taiyin meridian of the hand (LU9) 31.79 (3.51) 38.17 (3.77) .017a
 Jueyin meridian of the hand (PC7) 29.89 (3.48) 35.89 (3.45) .040a
 Shaoyin meridian of the hand (HT7) 27.75 (3.37) 35.81 (3.64) .006a
 Taiyin meridian of the foot (SP3) 20.34 (3.19) 24.30 (3.13) .031a
 Jueyin meridian of the foot (LR3) 20.96 (1.96) 27.63 (3.00) .004a
 Shaoyin meridian of the foot (KI4) 21.24 (2.37) 27.50 (2.99) .026a
Yang Meridian (acupoint)
 Taiyang meridian of the hand (SI4) 28.32 (3.53) 35.34 (4.39) .024a
 Shaoyang meridian of the hand (TE4) 34.50 (3.22) 38.67 (4.21) .154
 Yangming meridian of the hand (LI5) 31.14 (3.28) 36.01 (4.20) .072
 Taiyang meridian of the foot (BL65) 24.06 (3.14) 28.74 (2.93) .046a
 Shaoyang meridian of the foot (GB40) 15.15 (1.61) 18.44 (2.25) .051
 Yangming meridian of the foot (ST42) 21.90 (2.43) 26.18 (3.09) .070
Mean of yin meridians 25.33 (2.79) 31.55 (3.02) .010a
Mean of yang meridians 26.10 (2.59) 30.97 (3.28) .015a
P value .904 .234

Abbreviation: SEM, standard error of the mean.

a

P < .05 with statistical significance.

The Efficacy of KSY in Relieving Cancer-Related Symptoms and Improving QoL

Table 1 shows the improvement in cancer-related symptoms and QoL measures after the KSY intervention. All cancer-related symptoms except anemia and diarrhea/constipation showed significant improvement. After 2 weeks of the KSY medication, the severity of fatigue, general performance, insomonia, and nausea/vomitting had improved significantly (P < .05). Unsurprisingly, participants reported great improvements in QoL, as shown in responses to both the WHO-BREF and SF-12 (Table 5). In the WHO-BREF questionnaire, scores improved significantly in the physical, psychological, and social scales. In the SF-12 questionnaire, the phycial health composite score also increased significantly.

Table 5.

Comparison of Quality of Life (QoL) Scores Before and After Kuan-Sin-Yin Intervention (n = 52).

QoL Before, Mean (SD) After, Mean (SD) P Value
WHO-BREF
 Physical 62.68 (16.32) 67.8 (10.37) .008a
 Psychological 67.2 (13.42) 70.98 (8.96) .009a
 Social 65.98 (16.40) 70.49 (9.41) .028a
 Environmental 68.66 (13.28) 71.22 (9.28) .090
SF-12
 PCS 36.12 (11.63) 39.99 (10.82) .006a
 MCS 45.12 (9.05) 45.61 (7.72) .731

Abbreviations: SD, standard deviation; WHO-BREF, Brief World Health Organization Quality of Life Questionnaire; SF-12, 12-Item Short Form Health Survey; PCS, Physical Health Composite Score; MCS, Mental Health Composite Score.

a

P < .05 with statistical significance.

Discussion

Our results confirmed the hypothesis that the KSY intervention may improve AD in mCRC patients, as reflected in improvements in HRV, meridian electrical conductivity, cancer-related symptoms, and QoL.

KSY Regulates the AD Via Promotion of the Vagal/Sympathetic Dynamic Balance

The ANS controls organ activity and is largely involuntary. Multiple conditions, such as advanced cancer status, may impair its function and lead to AD.35 The ANS comprises the sympathetic system (which helps the body use energy) and the vagal system (which helps conserve energy and promotes healing); they operate together in a dynamic balance, as in the TCM concept of yin and yang energy. When the sympathetic system calls up more energy, as during severe illness or stress, the ANS is thrown out of balance.36 A more active sympathetic system, which dominates the vagal system, has been linked with conditions such as cardiovascular disease and mortality.37 Patients with advanced cancer have symptoms consistent with autonomical insufficiency. Previous studies report significantly higher norepinephrine and lower HRV levels in patients with cancer-related fatigue; lower HRV has also been linked to higher levels of chronic systemic inflammation.1,38

The results of our study showed that the KSY improved the HRV parameters of SDNN (HRV activity), HF, and RMMSD, which may indicate elevated vagal activity. Previous studies have shown that HF power reflects primarily vagal influences; LF power reflects both sympathetic and vagal influences.37 Translated into clinical implication, the significant increase in SDNN (HRV activity), an index for total ANS activity, means that the participants’ autonomic activity and adaptability were greater after the KSY intervention. This phenomenon is also reflected in the increase in the HF (vagal nerve systemic activity), and RMMSD values. Because KSY is a complex decoction based on the TCM theory of promoting qi energy over the whole body and regulating the ANS dynamic balance, it not only stimulates the vagal tone but also positively affects the sympathetic tone. With the increase seen in the vagal system, the general energy (qi) increased, possibly reflecting the greater ability of the vegal system to conserve energy for healing. Therefore, patients benefit with more adaptability and vitality as a result of the improvement in AD.

The TCM Yin/Yang Theory Applied to AD

The TCM theory of yin/yang can be applied to the effect of KSY on AD. Many studies have measured the electrical conductivity over specific acupoints in TCM meridians and applied these results to activity of the autonomic nerve system.6,15,30,39 We observed a much greater increase in qi energy in the yin meridians than in the yang meridians, a finding that corresponds to the greater increase in vagal tone than in sympathetic tone, as shown by HRV analysis. This result suggests that the yin/yang concept may be compatible with the vagal/sympathetic systems. According to TCM, yin and yang can be characterized as polar opposites just like the vagal and sympathetic systems that control the organs. A more subtle interpretation of the yin/yang principle includes an acknowledgment of the crucial role of the interrelation of the opposites. As with the autonomic control of the heart or any other organ, the interaction between the vagus and sympathetic systems, classically characterized as opposite and reciprocal, can also be both synchronous and synergistic.40 In fact, the studies of Paton et al41 proved that the vagus and sympathetic inputs to the heart should no longer be seen as polar antagonists, but more like the yin and yang: different but often complementary. A general interpretation of the process of autonomic control made by Berntson et al42 in 1991 coincides with the yin/yang theory. Only when the dynamic balance of yin/yang (which corresponds to the vagal/sympathetic system) was reached could the human maintain a healthy status. KSY enhances the qi flow, the so-called “energy,” which may promote the dynamic balance of yin/yang seen in the vagal/sympathetic system.

The Possible Mechanism by Which KSY Improves Cancer-Related Symptoms and QoL

KSY improved most cancer-related symptoms (insomonia, nausea/vomtting, anorexia, pain, fatigue, and performance status) except for anemia and diarrhea/consipatation. The ability of KSY to improve the nausea/vomiting, anorexia, and fatigue may be related to the increase in vagal activity and HRV, which is associated with modulation of the immune system and anti-inflammation.43 The common mechanism seems to involve lower levels of proinflammatory cytokines such as interleukin (IL)-1 and IL-6 and tumor necrosis factor (TNF). Importantly, increased vagal activity and acetylcholine (the primary parasympathetic neurotransmitter) have been shown to attenuate the release of these proinflammatory cytokines, and sympathetic hyperactivity is associated with their increased production.44,45 We posit that changes in the cytokine levels may account for the improvements in nausea/vomiting, anorexia, and fatigue. Future studies should specifically investigate the mechanisms of microenvironment change associated with KSY in colon cancer.

Meanwhile, KSY may have improved insomnia via regulating vagal activity and increasing the HRV activity (SDNN), consistent with the study by Ter Horst.46 He found that emotional arousal and physiological irritability were associated with a decrease in HRV attributed to a general inhibitory role of the medial prefrontal cortex via the vagal system.46 Other studies have shown that SDNN (HRV) is an index of central-peripheral neural feedback and integration of the central nervous system-ANS through the regulation of the inhibitory neurotransmitter γ-aminobutyric acid.37 KSY may have improved insomnia by stimulating hypervagal activity, reflected in the increase in HRV and yin meridian electrical conductivity.

KSY may have improved the cancer-related symptoms and QoL through the mechanism of regulating the AD but did not affect hematopoiesis. The irinotecan or oxaliplatin chemotherapy regimen in mCRC has side effects of marrow suppression and diarrhea, symptoms that KSY did not improve.

Pharmacological Explanation for the Effect of KSY

TCM pharmacopuncture or acupoint stimulation to regulate the meridian energy has been shown to be effective in reducing cancer pain, fatigue, chemotherapy-related nausea/vomiting, and anorexia.47,48 This is not the first study to show that TCM can be used as an adjuvant therapy to reduce chemotherapy toxicity and improve patient QoL. Other studies indicate that TCM may prolong survival, enhance immediate tumor response, and improve physical performance and energy in some cancer patients.49 The pharmacological explanation suggests that the effect of KSY may be related to the association of low vagal tone with an exaggerated proinflammatory profile because of the cholinergic anti-inflammatory pathways of the parasympathetic nervous system.38 KSY not only increased the vagal tone, but may also have reduced inflammation, thanks to the component Glycyrrhiza uralensis,18 and stimulated the immune system, thanks to the component Poria cocos.16 In fact, a recent systematic review found that advanced colon cancer patients receiving chemotherapy benefitted from adjuvant TCM ingredients such as Codonopsis pilosula, Atractylodes macrocephala, Poria cocos, or Astragalus membranaceus (including ingredients in KSY); they had improved tumor response rates, survival, and QoL, in addition to fewer adverse events.50

The Mechanism of KSY in the Cancer Cell Microenvironment

Each ingredient of KSY has been shown to have anti-inflammatory and immune modulation effects via regulation of cytokine secretion.16,18,21,22 However, we do not yet know the possible synergistic or buffering interactions between these herbs in terms of the overall effect of KSY. A very recent study using a mouse tumor model indicated that KSY can impair tumor growth independent of its immune effect because neither the number of tumor-infiltrated lymphocytes nor the expression of anticancer-associated cytokines (TNF-α, interferon-γ, IL-2, and IL-12) were increased after KSY treatment.9 KSY was shown to inhibit cancer more through the suppression of proliferation of cancer cells than through the enhancement of apoptosis. As the expression of the Ki-67 protein has been well demonstrated to be strictly associated with cancer cell proliferation, the effect of KSY on the cancer microenvironment is via inhibiting Ki-67 expression and increasing the expression of p53 and p21.9 Moreover, p53 is a protein that serves as a tumor suppressor, and p21 is a known downstream gene of p53. The expression of p53 and p21 may contribute to the downregulation of cyclin-dependent kinases and impair the cancer cell cycle.51 Becuase multiple molecular mechanisms have been proposed to regulate the p53-modulated pathway and determine the fate of tumor cells,52 further explorations of these subtle mechanisms are worth exploration.

Limitations

The current study has some limitations. First, no control group was included to measure the possible bias and placebo effects. Second, although the improvement in the vagal tone (HF) was larger than that in the sympathetic tone (LF) in HRV assessment, we could not determine the relationship between HRV modulation and changes in the meridian levels. Even after controlling for the environmental temperature, test pressure, and contact acupoints in this study, skin moisture and the presence of sweat ducts may confound the results obtainable from current electrodermal devices. So far, we can only posit that the concept of yin/yang is relevant to the vagal/sympathetic system based on the similarity of characteristics shown in this and other studies. Based on the tumor-suppressive effects of KSY, the results of this study certainly illustrate the effect of regulating AD in mCRC patients. A larger sample will be needed in a future study to draw stronger conclusions.

Conclusion

In this study, we found that KSY may promote an increase in meridian energy, regulate autonomic activity, and increase HRV to help mCRC patients regain dynamic balance and improve AD, cancer-related symptoms, and QoL. Clinically, KSY helps cancer patients have fewer symptoms and greater QoL. With regard to the future directions for research in the field of TCM in mCRC, because this study suggests the safety and efficacy of adjuvant KSY in mCRC patients, randomized trials should be conducted. We also encourage further studies into the mechanisms by which it works in the tumor microenvironment, which would provide more molecular, pharmacological, or relevant clinical evidence for TCM in mCRC.

Supplementary Material

Supplementary material
Supplementary material
Supplementary material
SupplementaryMaterial3.docx (540.7KB, docx)

Acknowledgments

The authors sincerely thank all patients who participated in this study and colleagues at Lin-Sen (TCM) branch, Taipei City Hospital, Taiwan, as well as all related colleagues who assisted in this study (Government IRB No. TCHIRB-1020127-E).

Footnotes

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

  • 1. Stone CA, Kenny RA, Nolan B, Lawlor PG. Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessment. BMC Palliat Care. 2012;11:3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Gabella G. Meeting report: the autonomic nervous system in health and disease. J Auton Nerv Syst. 1987;19:175-178. [DOI] [PubMed] [Google Scholar]
  • 3. Bruera E, Chadwick S, Fox R, Hanson J, MacDonald N. Study of cardiovascular autonomic insufficiency in advanced cancer patients. Cancer Treat Rep. 1986;70:1383-1387. [PubMed] [Google Scholar]
  • 4. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006;107:2949-2957. [DOI] [PubMed] [Google Scholar]
  • 5. Chang YY, Wang LY, Liu CY, Hsu CH. Effect of Kuan Sin Yin and Buddhism-based program on quality of life in cancer outpatients: a pilot study. Regist Chin Herb Med J. 2014;111:5-13. [Google Scholar]
  • 6. Lee CT, Chang YH, Lin WY, et al. Applications of meridian electrical conductance for renal colic: a prospective study. J Altern Complement Med. 2010;16:861-866. [DOI] [PubMed] [Google Scholar]
  • 7. Cai J, Wang H, Zhou S, Wu B, Song HR, Xuan ZR. Effect of Sijunzi decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2008;6:37-40. [DOI] [PubMed] [Google Scholar]
  • 8. Zhang B, Huang G, Zhang Y, Chen X, Hu P, Xu B. Clinical observation on prevention of “jia wei si jun zi tang” from damage of hepatic reserving function after intervention of liver cancer. Zhong Yao Cai. 2004;27:387-389. [PubMed] [Google Scholar]
  • 9. Li TF, Lin CC, Tsai HP, Hsu CH, Fu SL. Effects of Kuan-Sin-Yin decoction on immunomodulation and tumorigenesis in mouse tumor models. BMC Complement Altern Med. 2014;14:488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Nakatani Y. Skin electric resistance and Ryodoraku. J Auton Nerv Syst. 1956;6:52. [Google Scholar]
  • 11. Lin ML, Wu HC, Hsieh YH, et al. Evaluation of the effect of laser acupuncture and cupping with ryodoraku and visual analog scale on low back pain. Evid Based Complement Alternat Med. 2012;2012:521612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Walter S, Bodemar G, Hallböök O, Thorell LH. Sympathetic (electrodermal) activity during repeated maximal rectal distensions in patients with irritable bowel syndrome and constipation. Neurogastroenterol Motil. 2008;20:43-52. [DOI] [PubMed] [Google Scholar]
  • 13. Qiao ZG, Vaeroy H, Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol. 1991;18:1383-1389. [PubMed] [Google Scholar]
  • 14. Guo Y, Palmer JL, Strasser F, Yusuf SW, Bruera E. Heart rate variability as a measure of autonomic dysfunction in men with advanced cancer. Eur J Cancer Care (Engl). 2013;22:612-616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Chien LW, Chen FC, Hu HY, Liu CF. Correlation of electrical conductance in meridian and autonomic nervous activity after auricular acupressure in middle-aged women. J Altern Complement Med. 2014;20:635-641. [DOI] [PubMed] [Google Scholar]
  • 16. Chang HH, Yeh CH, Sheu F. A novel immunomodulatory protein from Poria cocos induces Toll-like receptor 4-dependent activation within mouse peritoneal macrophages. J Agric Food Chem. 2009;57:6129-6139. [DOI] [PubMed] [Google Scholar]
  • 17. Chao WW, Kuo YH, Li WC, Lin BF. The production of nitric oxide and prostaglandin E2 in peritoneal macrophages is inhibited by Andrographis paniculata, Angelica sinensis and Morus alba ethyl acetate fractions. J Ethnopharmacol. 2009;122:68-75. [DOI] [PubMed] [Google Scholar]
  • 18. Feng C, Wang H, Yao C, Zhang J, Tian Z. Diammonium glycyrrhizinate, a component of traditional Chinese medicine Gan-Cao, prevents murine T-cell-mediated fulminant hepatitis in IL-10- and IL-6-dependent manners. Int Immunopharmacol. 2007;7:1292-1298. [DOI] [PubMed] [Google Scholar]
  • 19. Jin C, Zhang PJ, Bao CQ, et al. Protective effects of Atractylodes macrocephala polysaccharide on liver ischemia-reperfusion injury and its possible mechanism in rats. Am J Chin Med. 2011;39:489-502. [DOI] [PubMed] [Google Scholar]
  • 20. Lin HM, Yen FL, Ng LT, Lin CC. Protective effects of Ligustrum lucidum fruit extract on acute butylated hydroxytoluene-induced oxidative stress in rats. J Ethnopharmacol. 2007;111:129-136. [DOI] [PubMed] [Google Scholar]
  • 21. Oh HM, Kang YJ, Kim SH, et al. Agastache rugosa leaf extract inhibits the iNOS expression in ROS 17/2.8 cells activated with TNF-alpha and IL-1beta. Arch Pharm Res. 2005;28:305-310. [DOI] [PubMed] [Google Scholar]
  • 22. Sun YX. Immunological adjuvant effect of a water-soluble polysaccharide, CPP, from the roots of Codonopsis pilosula on the immune responses to ovalbumin in mice. Chem Biodivers. 2009;6:890-896. [DOI] [PubMed] [Google Scholar]
  • 23. Xie B, Gong T, Tang M, et al. An approach based on HPLC-fingerprint and chemometrics to quality consistency evaluation of Liuwei Dihuang Pills produced by different manufacturers. J Pharm Biomed Anal. 2008;48:1261-1266. [DOI] [PubMed] [Google Scholar]
  • 24. Wendel JF, Schnabel A, Seelanan T. Bidirectional interlocus concerted evolution following allopolyploid speciation in cotton (Gossypium). Proc Natl Acad Sci U S A. 1995;92:280-284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Lee CJ, Cheng CH, Li YH, Liu CY, Hsu CH. A Chinese medicine, Kuan-Sin-Yin decoction, improves liver function in hepatitis B virus carriers: a randomized, controlled study. J Altern Complement Med. 2013;19:964-969. [DOI] [PubMed] [Google Scholar]
  • 26. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996;17:354-381. [PubMed] [Google Scholar]
  • 27. Pomeranz B, Macaulay RJ, Caudill MA, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol. 1985;248:151-153. [DOI] [PubMed] [Google Scholar]
  • 28. Liang WC, Yuan J, Sun DC, Lin MH. Changes in physiological parameters induced by indoor simulated driving: effect of lower body exercise at mid-term break. Sensors (Basel). 2009;9(9):6913-6933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Fadul N, Strasser F, Palmer JL, et al. The association between autonomic dysfunction and survival in male patients with advanced cancer: a preliminary report. J Pain Symptom Manage. 2010;39:283-290. [DOI] [PubMed] [Google Scholar]
  • 30. Chen MF, Yu HM, Li SF, You TJ. A complementary method for detecting qi vacuity. BMC Complement Altern Med. 2009;9:12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Lin WC, Chen YH, Xu JM, Chen DC, Chen WC, Lee CT. Application of skin electrical conductance of acupuncture meridians for ureteral calculus: a case report. Case Rep Nephrol. 2011;2011:413532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233. [DOI] [PubMed] [Google Scholar]
  • 34. Yao G, Chung CW, Yu CF, Wang JD. Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc. 2002;101:342-351. [PubMed] [Google Scholar]
  • 35. Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer. 2002;10:523-528. [DOI] [PubMed] [Google Scholar]
  • 36. Thayer JF, Sternberg E. Beyond heart rate variability: vagal regulation of allostatic systems. Ann N Y Acad Sci. 2006;1088:361-372. [DOI] [PubMed] [Google Scholar]
  • 37. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007;74:224-242. [DOI] [PubMed] [Google Scholar]
  • 38. Fagundes CP, Murray DM, Hwang BS, et al. Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology. 2011;36:1137-1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Ahn AC, Schnyer R, Conboy L, Laufer MR, Wayne PM. Electrodermal measures of Jing-Well points and their clinical relevance in endometriosis-related chronic pelvic pain. J Altern Complement Med. 2009;15:1293-1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Kollai M, Koizumi K. Reciprocal and non-reciprocal action of the vagal and sympathetic nerves innervating the heart. J Auton Nerv Syst. 1979;1:33-52. [DOI] [PubMed] [Google Scholar]
  • 41. Paton JF, Boscan P, Pickering AE, Nalivaiko E. The yin and yang of cardiac autonomic control: vago-sympathetic interactions revisited. Brain Res Brain Res Rev. 2005;49:555-565. [DOI] [PubMed] [Google Scholar]
  • 42. Berntson GG, Cacioppo JT, Quigley KS. Autonomic determinism: the modes of autonomic control, the doctrine of autonomic space, and the laws of autonomic constraint. Psychol Rev. 1991;98:459-487. [DOI] [PubMed] [Google Scholar]
  • 43. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu Rev Psychol. 2002;53:83-107. [DOI] [PubMed] [Google Scholar]
  • 44. Hefner J, Csef H, Kunzmann V. Stress and pancreatic carcinoma: β-adrenergic signaling and tumor biology. Dtsch Med Wochenschr. 2014;139:334-338. [DOI] [PubMed] [Google Scholar]
  • 45. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853-859. [DOI] [PubMed] [Google Scholar]
  • 46. Ter Horst GJ. Central autonomic control of the heart, angina, and pathogenic mechanisms of post-myocardial infarction depression. Eur J Morphol. 1999;37:257-266. [DOI] [PubMed] [Google Scholar]
  • 47. Bao Y, Kong X, Yang L, et al. Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Alternat Med. 2014;2014:170396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Shen Y, Liu L, Chiang JS, et al. Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea. Cancer. 2015;121:84-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Li SG, Chen HY, Ou-Yang CS, et al. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e57604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Chen M, May BH, Zhou IW, Xue CC, Zhang AL. FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. Phytother Res. 2014;28:976-991. [DOI] [PubMed] [Google Scholar]
  • 51. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol. 2010;3:1-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Carvajal LA, Manfredi JJ. Another fork in the road: life or death decisions by the tumour suppressor p53. EMBO Rep. 2013;14:414-421. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material
Supplementary material
Supplementary material
SupplementaryMaterial3.docx (540.7KB, docx)

Articles from Integrative Cancer Therapies are provided here courtesy of SAGE Publications

RESOURCES